AstraZeneca describes itself as a global, innovation-driven, integrated biopharmaceutical company with a focus on six areas of healthcare. These include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation
To further advance the delivery of medicines which make a meaningful difference to patient care, AstraZeneca recently announced that it would concentrate its R&D efforts into fewer, more entrepreneurial units in a narrower range of disease areas, as well as spend a greater proportion of funds on projects with external researchers.
One consequence of this strategic reorientation involves the closure of two research units: Lund in the south of Sweden and Charnwood in Loughborough in the UK. Both locations are specialised in respiratory and inflammatory diseases which will now be transferred to the Mölndal site just south of Göteborg.
The buildup in Mölndal is currently on-going and will be completed by the end of 2011. Asked to comment on how the integration is proceeding, Site Manager Peter Nyström says, “Everyone across all three locations is working hard to realise a world class Respiratory & Inflammation research capability alongside the established areas of Cardiovascular & Gastrointestinal. Furthermore, the surrounding society is providing admirable support when it comes to everything from schools and housing for relocated staff, to investments in order to provide a solid academic base also in the area of R&I.”